CF PharmTech, Inc.
Research CF PharmTech, Inc. (2652.HK) on Bullrun: market cap HKD 2.58B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2652.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 2.58B
- Financial periodFY2025
- RevenueCNY 432.52M
- Revenue growth-28.8%
- Net incomeCNY 2.49M
- Free cash flow-CNY 261.42M
- Gross margin75.8%
Valuation Snapshot
latest market cap is HKD 2.58B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 432.52M | CNY 2.49M | -CNY 261.42M | 75.8% | 0.01 | CNY 414.90M | CNY 145.56M | CNY 1.47B |
| FY2024 | CNY 607.75M | CNY 21.09M | -CNY 104.19M | 80.9% | 0.07 | CNY 81.94M | CNY 79.10M | CNY 939.28M |
| FY2023 | CNY 556.42M | CNY 31.73M | -CNY 22.04M | 82.2% | 0.1 | CNY 70.61M | CNY 21.91M | CNY 910.02M |
| FY2022 | CNY 349.13M | -CNY 49.40M | -CNY 75.13M | 76.6% | -0.16 | CNY 74.84M | CNY 1.50M | CNY 861.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.58B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About CF PharmTech, Inc.
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CF PharmTech, Inc.'s market cap?
CF PharmTech, Inc.'s market capitalization is HKD 2.58B.
What does CF PharmTech, Inc. do?
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name.